8-OH-DPAT-induced release of hippocampal noradrenaline in vivo: evidence for a role of both 5-HT1A and dopamine D1 receptors

doi:10.1016/S0014-2999(96)00560-2

European Journal of Pharmacology

Volume 314, Issue 3, 31 October 1996, Pages 285-291

https://doi.org/10.1016/S0014-2999(96)00560-2 Get rights and content

Abstract

Here we investigate the effects of the novel selective 5-HT_1A receptor antagonist, N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]methyl]-N-(2-pyridinyl cyclo-hexanecarboxamide (WAY 100635), and the dopamine D₁ receptor antagonist, R-(+)-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1 H-3-benzazepin-7-ol (SCH 23390), on the increase in extracellular noradrenaline in rat hippocampus induced by the 5-HT_1A receptor agonist, 8-hydroxy-2-(di-N-propylamino)tetralin (8-OH-DPAT). 8-OH-DPAT (0.1 and 1 mg/kg s.c.) caused a dose-related increase in extracellular noradrenaline. WAY 100635 (0.3 and 1 mg/kg s.c.) did not block the release of noradrenaline induced by the higher dose of 8-OH-DPAT (1 mg/kg s.c.) but abolished the response to the lower dose (0.1 mg/kg s.c.). When administered alone, WAY 100635 (0.3 and 1 mg/kg s.c.) had no effect on extracellular noradrenaline. The postsynaptically mediated 5-HT behavioural syndrome induced by the higher dose of 8-OH-DPAT, in contrast to the increase in noradrenaline, was completely blocked by WAY 100635 (0.3 mg/kg s.c.). Finally, the noradrenaline response to 8-OH-DPAT (0.1 mg/kg s.c.) was blocked by SCH 23390 (0.5 mg/kg s.c.). Our data confirm that noradrenaline can be released by activation of 5-HT_1A receptors but show that these receptors are not tonically activated, and may be more sensitive to stimulation than classical postsynaptic 5-HT_1A receptors. A role for the dopamine D₁ receptor in the noradrenaline response to 8-OH-DPAT is also suggested.

References (32)

S. Consolo et al.
A critical role for D₁ receptors in the 5-HT_1A-mediated facilitation of in vivo acetylcholine release in rat frontal cortex
Brain Res.
(1996)
C.J.G. Done et al.
Biochemical evidence for the regulation of central noradrenergic activity by 5-HT_1A and 5-HT₂ receptors: microdialysis studies in the awake and anaesthetised rat
Neuropharmacology
(1994)
A. Fletcher et al.
Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY 100635, a potent, selective and silent 5-HT_1A receptor antagonist
Behav. Brain Res.
(1995)
S.E. Gartside et al.
Effects of MDL 73005EF on central pre- and postsynaptic 5-HT_1A receptor function in the rat in vivo
Eur. J. Pharmacol.
(1990)
E. Gorea et al.
Serotoninergic regulation of noradrenergic coerulean neurones: electrophysiological evidence for the involvement of 5-HT₂ receptors
Eur. J. Pharmacol.
(1988)
P.E. Hicks et al.
5-HT receptor antagonist properties of SCH 23390 in vascular smooth muscle and brain
Eur. J. Pharmacol.
(1984)
S. Hjorth et al.
Mixed agonist/antagonist properties of NAN-190 at 5-HT_1A receptors: behavioural and in vivo brain microdialysis studies
Life Sci.
(1990)
K. Rasmussen et al.
Effects of hallucinogens on spontaneous and sensory-evoked locus coeruleus unit activity in the rat: reversal by selective 5-HT₂ antagonists
Brain Res.
(1986)
B. Renaud et al.
Effect of 5,6-dihydroxytryptamine on tyrosine hydroxylase activity in central cate-cholamine neurons of the rat
Biochem. Pharmacol.
(1975)
C. Routledge et al.
Neurochemical profile of the selective and silent 5-HT_1A receptor antagonist WAY100135: an in vivo microdialysis study
Eur. J. Pharmacol.
(1993)

T. Sharp et al.

Application of brain microdialysis to study the pharmacology of the 5-HT_1A autoreceptor

J. Neurosci. Meth.

(1990)

T.S. Shippenberg

Conditioned reinforcing effects of 8-hydroxy-2-(di-N-propylamino)tetralin: involvement of 5-hydroxytryptamine_1A and D₁ dopamine receptors

Neurosci. Lett.

(1991)

L. Arborelius et al.

(R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex

Acta Physiol. Scand.

(1993)

L. Arborelius et al.

The 5-HT_1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons

Naunyn-Schmiedeberg's Arch. Pharmacol.

(1993)

S. Biscoff et al.

Interaction of the D₁ receptor antagonist SCH 23390 with the central 5-HT system: radioligand binding studies, measurements of biochemical parameters and effects on L-5-HTP

J. Rec. Res.

(1988)

D.S. Charney et al.

Serotonin-specific drugs for anxiety and depressive disorders

Annu. Rev. Med.

(1990)

Cited by (38)

Role of central serotonin and noradrenaline interactions in the antidepressants’ action: Electrophysiological and neurochemical evidence
2021, Progress in Brain Research
Citation Excerpt :
At least in conscious rat, they found that when the tonic 5-HT2A receptor inhibitory influence is removed, either by blocking 5-HT2 receptors or by decreasing 5-HT release through activation of 5-HT1A autoreceptors, NA release is increased (Done and Sharp, 1992, 1994). However, concerning the 5-HT1A receptor excitatory influence on NA release by 5-HT1A receptors agonists, it has been suggested that this influence may be due to a postsynaptic interaction with the DA and ACh systems, since this effect of 5-HT1A receptors agonists on NA efflux is not abolished in rat pretreated with either the 5,7-DHT neurotoxin or a 5-HT synthesis inhibitor (Chen and Reith, 1995; Consolo et al., 1996; Hajós-Korcsok et al., 1999; Hajos-Korcsok and Sharp, 1996; Piercey et al., 1994; Suzuki et al., 1995). 5-HT3 receptor inhibitory influence on NA release has been described in vitro and in vivo in both rat hypothalamus and hippocampus, presumably via an indirect action on GABAergic or DAergic systems (Blandina et al., 1991; Matsumoto et al., 1995).
The development of antidepressant drugs, in the last 6 decades, has been associated with theories based on a deficiency of serotonin (5-HT) and/or noradrenaline (NA) systems. Although the pathophysiology of major depression (MD) is not fully understood, numerous investigations have suggested that treatments with various classes of antidepressant drugs may lead to an enhanced 5-HT and/or adapted NA neurotransmissions. In this review, particular morpho-physiological aspects of these systems are first considered. Second, principal features of central 5-HT/NA interactions are examined. In this regard, the effects of the acute and sustained antidepressant administrations on these systems are discussed. Finally, future directions including novel therapeutic strategies are proposed.
Central fatigue theory and endurance exercise: Toward an interoceptive model
2018, Neuroscience and Biobehavioral Reviews
Citation Excerpt :
The processes by which 5-HT affects NE release are very similar to those affecting DA release. 5-HT1A receptors have been shown to stimulate NE release particularly in the hippocampus (Done and Sharp, 1992; Hajo´s-Korcsok and Sharp, 1996), frontal cortex (Hajo´s-Korcsok and Sharp, 1996), hypothalamus (Suzuki et al., 1995), and VTA (Chen and Reith, 1995). 5-HT1A receptors are probably located at the presynaptic terminals of GABAergic neurons (Katsurabayashi et al., 2003).
We propose a model of exercise-induced central fatigue based on interoception and motivation. Predictions of the expected sensory feedback are fed forward by the dorsolateral (DL) prefrontal cortex (PFC) to the anterior insula cortex (AIC). During exercise, the AIC receives feedback from lamina Ⅰ lateral spinothalamic and nucleus tractus solitarii medullothalamic pathways. The feedback is compared to the predictions in order to generate a current awareness state, which is forwarded to the anterior cingulate cortex (ACC), ventromedial (VM)PFC and lateral (L)PFC. The LPFC integrates the information and makes a decision as to whether to continue or stop. The decision is dependent upon interaction with the substantia nigra pars compacta and ventral tegmental area dopamine (DA), and locus coeruleus (LC)-norepinephrine (NE) systems. Phasic activation of DA and NE neurons appears to be necessary for maintenance of goal-related action but the VMPFC and ACC, which project to the LC, induce tonic NE activity when the rewards are thought to be not worth the cost thus fatigue is perceived.
The 5-HT<inf>1A/1B</inf>-receptor agonist eltoprazine increases both catecholamine release in the prefrontal cortex and dopamine release in the nucleus accumbens and decreases motivation for reward and “waiting” impulsivity, but increases “stopping” impulsivity
2017, European Journal of Pharmacology
The 5-HT_1A/1B-receptor agonist eltoprazine has a behavioral drug signature that resembles that of a variety of psychostimulant drugs, despite the differences in receptor binding profile. These psychostimulants are effective in treating impulsivity disorders, most likely because they increase norepinephrine (NE) and dopamine (DA) levels in the prefrontal cortex. Both amphetamine and methylphenidate, however, also increase dopamine levels in the nucleus accumbens (NAc), which has a significant role in motivation, pleasure, and reward.
How eltoprazine affects monoamine release in the medial prefrontal cortex (mPFC), the orbitofrontal cortex (OFC), and the NAc is unknown. It is also unknown whether eltoprazine affects different forms of impulsivity and brain reward mechanisms.
Therefore, in the present study, we investigate the effects of eltoprazine in rats in the following sequence: 1) the activity of the monoaminergic systems using in vivo microdialysis, 2) motivation for reward measured using the intracranial self-stimulation (ICSS) procedure, and finally, 3) “waiting” impulsivity in the delay-aversion task, and the “stopping” impulsivity in the stop-signal task.
The microdialysis studies clearly showed that eltoprazine increased DA and NE release in both the mPFC and OFC, but only increased DA concentration in the NAc. In contrast, eltoprazine decreased 5-HT release in the mPFC and NAc (undetectable in the OFC). Remarkably, eltoprazine decreased impulsive choice, but increased impulsive action. Furthermore, brain stimulation was less rewarding following eltoprazine treatment. These results further support the long-standing hypothesis that “waiting” and “stopping” impulsivity are regulated by distinct neural circuits, because 5-HT_1A/1B-receptor activation decreases impulsive choice, but increases impulsive action.
Involvement of 5-HT<inf>3</inf> receptors in the action of vortioxetine in rat brain: Focus on glutamatergic and GABAergic neurotransmission
2016, Neuropharmacology
The antidepressant vortioxetine is a 5-HT₃-R, 5-HT₇-R and 5-HT_1D-R antagonist, 5-HT_1B-R partial agonist, 5-HT_1A-R agonist, and serotonin (5-HT) transporter (SERT) inhibitor. Vortioxetine occupies all targets at high therapeutic doses and only SERT and 5-HT₃-R at low doses. Vortioxetine increases extracellular monoamine concentrations in rat forebrain more than selective serotonin reuptake inhibitors (SSRI) and shows pro-cognitive activity in preclinical models. Given its high affinity for 5-HT₃-R (Ki = 3.7 nM), selectively expressed in GABA interneurons, we hypothesized that vortioxetine may disinhibit glutamatergic and monoaminergic neurotransmission following 5-HT₃-R blockade.
Here we assessed vortioxetine effect on pyramidal neuron activity and extracellular 5-HT concentration using in vivo extracellular recordings of rat medial prefrontal cortex (mPFC) pyramidal neurons and microdialysis in mPFC and ventral hippocampus (vHPC). Vortioxetine, but not escitalopram, increased pyramidal neuron discharge in mPFC. This effect was prevented by SR57227A (5-HT₃-R agonist) and was mimicked by ondansetron (5-HT₃-R antagonist) and by escitalopram/ondansetron combinations. In microdialysis experiments, ondansetron augmented the 5-HT-enhancing effect of escitalopram in mPFC and vHPC. Local ondansetron in vHPC augmented escitalopram effect, indicating the participation of intrinsic mechanisms. Since 5-HT neurons express GABA_B receptors, we examined their putative involvement in controlling 5-HT release after 5-HT₃-R blockade. Co-perfusion of baclofen (but not muscimol) reversed the increased 5-HT levels produced by vortioxetine and escitalopram/ondansetron combinations in vHPC.
The present results suggest that vortioxetine increases glutamatergic and serotonergic neurotransmission in rat forebrain by blocking 5-HT₃ receptors in GABA interneurons.
Omega-3 fatty acid deficient male rats exhibit abnormal behavioral activation in the forced swim test following chronic fluoxetine treatment: Association with altered 5-HT<inf>1A</inf> and alpha<inf>2A</inf> adrenergic receptor expression
2014, Journal of Psychiatric Research
Citation Excerpt :
In contrast to the effects of acute or chronic SSRI treatment, acute or chronic treatment with selective noradrenergic reuptake inhibitors (SNRI), including reboxetine or desipramine robustly increase climbing behavior in the FST (Cryan et al., 2002, 2005; Detke et al., 1995, 1997; Page et al., 1999). It is relevant therefore that selective activation of 5-HT1A receptors increases locus coeruleus neuronal activity, and increase extracellular noradrenaline concentrations in the rat forebrain (Hajos-Korcsok and Sharp, 1996; Hajós-Korcsok et al., 1999). Together, these data suggest that the observed changes in pre- and/or postsynaptic 5-HT1A receptor expression in FLX-treated DEF rats may be directly associated with the increase in climbing behavior.
Omega-3 fatty acid deficiency during development leads to enduing alterations in central monoamine neurotransmission in rat brain. Here we investigated the effects of omega-3 fatty acid deficiency on behavioral and neurochemical responses to chronic fluoxetine (FLX) treatment. Male rats were fed diets with (CON, n = 34) or without (DEF, n = 30) the omega-3 fatty acid precursor alpha-linolenic acid (ALA) during peri-adolescent development (P21–P90). A subset of CON (n = 14) and DEF (n = 12) rats were administered FLX (10 mg/kg/d) through their drinking water for 30 d beginning on P60. The forced swimming test (FST) was initiated on P90, and regional brain mRNA markers of serotonin and noradrenaline neurotransmission were determined. Dietary ALA depletion led to significant reductions in frontal cortex docosahexaenoic acid (DHA, 22:6n-3) composition in DEF (−26%, p = 0.0001) and DEF + FLX (−32%, p = 0.0001) rats. Plasma FLX and norfluoxetine concentrations did not different between FLX-treated DEF and CON rats. During the 15-min FST pretest, DEF + FLX rats exhibited significantly greater climbing behavior compared with CON + FLX rats. During the 5-min test trial, FLX treatment reduced immobility and increased swimming in CON and DEF rats, and only DEF + FLX rats exhibited significant elevations in climbing behavior. DEF + FLX rats exhibited greater midbrain, and lower frontal cortex, 5-HT_1A mRNA expression compared with all groups including CON + FLX rats. DEF + FLX rats also exhibited greater midbrain alpha_2A adrenergic receptor mRNA expression which was positively correlated with climbing behavior in the FST. These preclinical data demonstrate that low omega-3 fatty acid status leads to abnormal behavioral and neurochemical responses to chronic FLX treatment in male rats.
Serotonin receptors involved in antidepressant effects
2013, Pharmacology and Therapeutics
The neurotransmitter serotonin (5-hdroxytryptamine; 5-HT) has been implicated in the pathophysiology and treatment of major depression since the serendipitous discovery of antidepressant drugs in the 1950s. However, despite the generalised use of serotonin-enhancing drugs, such as the selective serotonin reuptake inhibitors (SSRIs) and the dual serotonin and norepinephrine reuptake inhibitors (SNRIs), the exact neurobiological mechanisms involved in the therapeutic action of these drugs are poorly understood. Better knowledge of these mechanisms may help to identify new therapeutic targets and to overcome the two main limitations of current treatments: reduced efficacy and slowness of action. Here I review the preclinical and clinical evidence supporting the involvement of different 5-HT receptors in the therapeutic action of antidepressant drugs. Presynaptic 5-HT_1A and 5-HT_1B autoreceptors play a major detrimental role in antidepressant treatments, as their activation by the excess of the active (extracellular) 5-HT fraction produced by serotonin transporter (SERT) blockade reduces presynaptic serotonergic function. Conversely, stimulation of postsynaptic 5-HT_1A receptors in corticolimbic networks appears beneficial for the antidepressant action. The 5-HT₂ receptor family is also involved as 5-HT_2A/2C receptor blockade improves the antidepressant action of SSRIs, and recent data suggest that 5-HT_2B receptor activation enhances serotonergic activity. Less is known from the rest of postsynaptic 5-HT receptors. However, 5-HT₃ receptor blockade augments the 5-HT increase evoked by SERT inhibition, and 5-HT₄ receptor activation may have antidepressant effects on its own. Finally, blockade of 5-HT₆ and 5-HT₇ receptors appears also to augment the antidepressant effects of SERT inhibition.

View all citing articles on Scopus

View full text

8-OH-DPAT-induced release of hippocampal noradrenaline in vivo: evidence for a role of both 5-HT1A and dopamine D1 receptors

Abstract

Brain Res.

Neuropharmacology

Behav. Brain Res.

Eur. J. Pharmacol.

Eur. J. Pharmacol.

Eur. J. Pharmacol.

Life Sci.

Brain Res.

Biochem. Pharmacol.

Eur. J. Pharmacol.

J. Neurosci. Meth.

Neurosci. Lett.

(R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex

Acta Physiol. Scand.

The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons

Naunyn-Schmiedeberg's Arch. Pharmacol.

Interaction of the D1 receptor antagonist SCH 23390 with the central 5-HT system: radioligand binding studies, measurements of biochemical parameters and effects on L-5-HTP

J. Rec. Res.

Serotonin-specific drugs for anxiety and depressive disorders

Annu. Rev. Med.

8-OH-DPAT-induced release of hippocampal noradrenaline in vivo: evidence for a role of both 5-HT_1A and dopamine D₁ receptors

The 5-HT_1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons

Interaction of the D₁ receptor antagonist SCH 23390 with the central 5-HT system: radioligand binding studies, measurements of biochemical parameters and effects on L-5-HTP